SCLX Scilex Holding
- 0.881
- +0.020+2.29%
- 0.879
- -0.001-0.16%
Scilex Holding News
Scilex Falls on Direct Offering to Raise $15M
Scilex Holding Company Announces $15M Registered Direct Offering Of 15M Shares At $1.00/Share
Scilex Holding Company Announces $15M Registered Direct Offering Of 15M Shares At $1.00/Share
Scilex Issues Preliminary Q1 Sales Results for ZTlido
Scilex Holding (SCLX) said Tuesday that Q1 net sales of ZTlido are expected to be between $12 million and $13 million, compared with $10.6 million in Q1 2023. The company also said that it plans to re
Scilex to Reduce R&D Expenses in 2024, Comments on Actions Post Change Healthcare Cyberattack
Scilex Holding Preliminary Q1 Net Sales For ZTlido Were $12M-$13M; Q1 Gross Sales For ZTlido Were $34M-$38M; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the Addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Scilex Holding Company (Nasdaq: SCLX）today announced launching of co-pay programs for both ZTlido and ELYXYB with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0.
Scilex Holding Says U.S. Bankruptcy Court Extended Lockup Period on Shares Previously Distributed by Sorrento to Its Stockholders as a Dividend >SCLX
Scilex Holding Says U.S. Bankruptcy Court Extended Lockup Period on Shares Previously Distributed by Sorrento to Its Stockholders as a Dividend >SCLX
Scilex Holding Ends Equity Purchase Deal With Yorkville
Scilex Holding Co And Ya II PN Mutually Agreed To Terminate Amended And Restated Standby Equity Purchase Agreement, Dated As Of Feb 8, 2023
Scilex Holding Co And Ya II PN Mutually Agreed To Terminate Amended And Restated Standby Equity Purchase Agreement, Dated As Of Feb 8, 2023
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
Scilex has been working with its co-pay savings card adjudicators to resolve the recent breakdown of processing of insurance claims by Change Healthcare, following a cyber-attack on Change Healthcare.
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label
Scilex Holding (SCLX) said Wednesday it plans to seek approval from the US Food and Drug Administration to change the label of gout drug Gloperba to add dosing guidance for people with renal impairmen
Scilex Holding To Seek Approval Fro MFDA For Modification Of Gloperba To Include
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
Scilex Holding Company Announces Seeking Approval From the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients With Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed
Scilex Holding Company (Nasdaq: SCLX）today announced it will seek approval from the FDA for the modification of the Gloperba label to include its ability to utilize dosing flexibility of liquid formulation.
Scilex Holding Repays the Remaining Balance of Convertible Debentures
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Scilex Holding Company (Nasdaq: SCLX）today announced that it has paid off the remaining balance of approx. $1,300,000 under the convertible debentures (the "Convertible Debentures") previously issued and sold to YA II PN, Ltd. ("Yorkville") in March 2023.
Scilex Holding Company Provides Responses To Product Composition Questions Related To Its ELYXYB Patent In Canada For A New Drug Submission Under Review By Health Canada
ELYXYB is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1According to market data from 2018, it was
With A 27% Price Drop For Scilex Holding Company (NASDAQ:SCLX) You'll Still Get What You Pay For
The Scilex Holding Company (NASDAQ:SCLX) share price has softened a substantial 27% over the previous 30 days, handing back much of the gains the stock has made lately. For any long-term shareholde
Scilex Holding Announces Issuance of Halal Certification for Its ZTlido Product by Circle H International, Inc.
Scilex Holding Company (Nasdaq: SCLX）today announced that it received Halal Certification of its commercial product ZTlido, indicating that ZTlido has undergone rigorous assessment to determine that it is permissible or acceptable in accordance with Islamic standards.
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs
Scilex (SCLX) said Friday that the US Bankruptcy Court for the Southern District of Texas approved a settlement and mutual release agreement with Virpax Pharmaceuticals The pain-relief-focused pharmac
Analysis
Price Target
No Data
